Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6689277rdf:typepubmed:Citationlld:pubmed
pubmed-article:6689277lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:6689277lifeskim:mentionsumls-concept:C0039789lld:lifeskim
pubmed-article:6689277lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:6689277lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:6689277lifeskim:mentionsumls-concept:C1521801lld:lifeskim
pubmed-article:6689277lifeskim:mentionsumls-concept:C0065961lld:lifeskim
pubmed-article:6689277pubmed:issue4lld:pubmed
pubmed-article:6689277pubmed:dateCreated1984-3-20lld:pubmed
pubmed-article:6689277pubmed:abstractTextThe bioavailability and pharmacokinetics of 10 mg of mepindolol sulphate and of 25 mg of hydrochlorothiazide were compared in a cross-over design in five healthy volunteers after the administration of either the single drugs (Corindolan and Esidrix) or in combination (Tenesor). Maximum concentrations of mepindolol in the plasma of 25 ng ml-1 were achieved 1.6 h after both treatments and the half-life of disposition was calculated to be 4-5 h, being somewhat longer after the combination tablet. The amount of hydrochlorothiazide renally eliminated up to 48 h after drug intake was about 60 per cent of the dose. The half-life of renal excretion was 3 h. The two formulations of mepindolol sulphate and hydrochlorothiazide proved to be bioequivalent with a tendency to better mepindolol bioavailability in the combination form.lld:pubmed
pubmed-article:6689277pubmed:languageenglld:pubmed
pubmed-article:6689277pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6689277pubmed:citationSubsetIMlld:pubmed
pubmed-article:6689277pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6689277pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6689277pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6689277pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6689277pubmed:statusMEDLINElld:pubmed
pubmed-article:6689277pubmed:issn0142-2782lld:pubmed
pubmed-article:6689277pubmed:authorpubmed-author:KrauseWWlld:pubmed
pubmed-article:6689277pubmed:authorpubmed-author:LennertCClld:pubmed
pubmed-article:6689277pubmed:issnTypePrintlld:pubmed
pubmed-article:6689277pubmed:volume4lld:pubmed
pubmed-article:6689277pubmed:ownerNLMlld:pubmed
pubmed-article:6689277pubmed:authorsCompleteYlld:pubmed
pubmed-article:6689277pubmed:pagination339-45lld:pubmed
pubmed-article:6689277pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:6689277pubmed:meshHeadingpubmed-meshheading:6689277-...lld:pubmed
pubmed-article:6689277pubmed:meshHeadingpubmed-meshheading:6689277-...lld:pubmed
pubmed-article:6689277pubmed:meshHeadingpubmed-meshheading:6689277-...lld:pubmed
pubmed-article:6689277pubmed:meshHeadingpubmed-meshheading:6689277-...lld:pubmed
pubmed-article:6689277pubmed:meshHeadingpubmed-meshheading:6689277-...lld:pubmed
pubmed-article:6689277pubmed:meshHeadingpubmed-meshheading:6689277-...lld:pubmed
pubmed-article:6689277pubmed:meshHeadingpubmed-meshheading:6689277-...lld:pubmed
pubmed-article:6689277pubmed:meshHeadingpubmed-meshheading:6689277-...lld:pubmed
pubmed-article:6689277pubmed:meshHeadingpubmed-meshheading:6689277-...lld:pubmed
pubmed-article:6689277pubmed:meshHeadingpubmed-meshheading:6689277-...lld:pubmed
pubmed-article:6689277pubmed:meshHeadingpubmed-meshheading:6689277-...lld:pubmed
pubmed-article:6689277pubmed:articleTitlePharmacokinetics of mepindolol administered alone and in combination with hydrochlorothiazide--a bioequivalence study.lld:pubmed
pubmed-article:6689277pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6689277pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:6689277pubmed:publicationTypeControlled Clinical Triallld:pubmed